A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GDC-0326 | GDC-0326 is a potent and selective PI3Kα inhibitor with a Ki of 0.2 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1282514-88-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-101272. |  |
| GDC-0326 | GDC-0326 is a selective PI3Kα (α-Isoform of Phosphoinositide 3-Kinase) inhibitor. GDC-0326 is highly selective over other kinases. It has low plasma CL in human. In PI3 kinase family, there are four class I PI3K isoforms including α, β, δ, and γ and PI3Kα is the most commonly associated with cancers, so GDC-0326 may become a drug candidate for cancer treatment. Uses: Anti-cancer. Synonyms: GDC-0326; GDC 0326; GDC0326; (S)-2-((2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide. Grade: 98%. CAS No. 1282514-88-8. Molecular formula: C19H22N6O3. Mole weight: 382.42. |  |
| GDC-0334 | GDC-0334, a TRPA1 antagonist, is used for the treatment of TRPA1-mediated diseases, such as pain or asthma. Synonyms: (4R,5S)-4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-({5-(trifluoromethyl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]pyridin-4-yl}methyl)-L-prolinamide; 2-Pyrrolidinecarboxamide, 4-fluoro-1-[(4-fluorophenyl)sulfonyl]-5-methyl-N-[[5-(trifluoromethyl)-2-[2-(trifluoromethyl)-5-pyrimidinyl]-4-pyridinyl]methyl]-, (2S,4R,5S)-. Grade: ≥90%. CAS No. 1984824-54-5. Molecular formula: C24H19F8N5O3S. Mole weight: 609.49. | |
| GDC-0339 | GDC-0339, also called as SCHEMBL14801965, is a selective inhibitor of BaF3 PIM1 that has the potential for treatment of cancer. BaF3 PIM1: IC50= 43.6 nM; PIM1 LC-3K: IC50= 0.04 nM. Synonyms: 5-amino-N-[5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methylpyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamideGDC-0339; GDC 0339; GDC0339; SCHEMBL14801965BDBM110706CS-4775; HY-16976; CS 4775; HY 16976; CS4775; HY16976; US8614206, 139. CAS No. 1428569-85-0. Molecular formula: C20H22F3N7OS. Mole weight: 465.50. | |
| GDC-0339 | GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1428569-85-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-16976. | |
| GDC-0349 | GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma. Synonyms: GDC-0349; GDC 0349; GDC0349; RG7603. CAS No. 1207360-89-1. Molecular formula: C24H32N6O3. Mole weight: 452.559. | |
| GDC-0425 | This active molecular is an selective Checkpoint kinase 1 (Chk1) inhibitors and it enhances gemcitabine efficacy in tumor xenograft models. GDC-0425 was safe and yielded responses in patients with a variety of cancers. In Oct 2013, GDC 0425 was in phase I trials for Solid tumours and Lymphoma (late-stage disease) in USA and France. In May 2014, Genentech completed a phase I trial in Lymphoma and Solid tumours (late-stage disease) in USA and France. Uses: Solid tumours and lymphoma. Synonyms: GDC-0425; GDC 0425; GDC0425; 5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile; RG-7602; RG 7602; RG7602. Grade: 98%. CAS No. 1200129-48-1. Molecular formula: C18H19N5O. Mole weight: 321.38. | |
| GDC-0449, SMO Inhibitor (2-Chloro-N- (4-chloro-3- (pyridine-2-yl) phenyl) -4- (methylsulfonyl) benzamide, HhAntag691) | A potent inhibitor of Smoothened (SMO), a key mediator of Hedgehog (Hh) signaling pathway. Inhibition of SMO renders the transcription factor GLI inactive, thus preventing the expression of genes that mediate the role of Hh on tumor growth. Group: Biochemicals. Grades: Highly Purified. CAS No. 879085-55-9. Pack Sizes: 5mg, 25mg. US Biological Life Sciences. |  Worldwide |
| GDC046 | GDC046 is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively. Synonyms: GDC-046; GDC 046. CAS No. 1258292-64-6. Molecular formula: C16H13Cl2N3O2. Mole weight: 350.20. | |
| GDC-0575 | GDC-0575 is a highly-selective, potent and oral small-molecule Chk1 inhibitor (IC50 = 1.2?nM). Uses: Protein kinase inhibitors. Synonyms: ARRY-575; RG7741; GDC0575. Grade: ≥98%. CAS No. 1196541-47-5. Molecular formula: C16H20BrN5O. Mole weight: 378.27. | |
| GDC-0575 | GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ARRY-575; RG7741. CAS No. 1196541-47-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112167. | |
| GDC0575 monohydrochloride | GDC0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. Synonyms: GDC0575 hydrochloride; ARRY-575 hydrochloride; (R)-N-(4-(3-Aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide hydrochloride. Grade: 95%. CAS No. 1196504-54-7. Molecular formula: C16H21BrClN5O. Mole weight: 414.73. | |
| GDC-0623 | GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. Synonyms: GDC0623; GDC-0632; GDC 0632; G868; G 868; G-868. CAS No. 1168091-68-6. Molecular formula: C16H14FIN4O3. Mole weight: 456.216. | |
| GDC-0623 | GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM). Uses: Scientific research. Category: Signaling pathways. Alternative Names: RG 7421; MEK inhibitor 1. CAS No. 1168091-68-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15610. | |
| GDC-0810 (ARN-810) | GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. Synonyms: GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046. Grade: 98%. CAS No. 1365888-06-7. Molecular formula: C26H20ClFN2O2. Mole weight: 446.91. | |
| GDC-0834 | GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1133432-49-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15427. | |
| GDC-0834 | GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human. Synonyms: GDC-0834; GDC0834; GDC 0834. CAS No. 1133432-46-8. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0837 | GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg) in a rat CIA model induced a decrease of ankle swelling and reduction of morphologic pathology in a dose-dependent manner. Synonyms: GDC-0837; GDC 0837; GDC0837. CAS No. 1133432-49-1. Molecular formula: C33H36N6O3S. Mole weight: 596.74. | |
| GDC-0853 | GDC-0853 is a Bruton's tyrosine kinase (BTK) inhibitor originated by Genentech. GDC-0853 can inhibit the activity of BTK and prevent the activation of the B-cell antigen receptor (BCR) signaling pathway. This leads to the inhibition of the growth of malignant B-cells that overexpress BTK. Phase III clinical trials for the treatment of Multiple sclerosis and Phase II clinical trials for the treatment of Chronic urticaria and Systemic lupus erythematosus are on-going. Uses: Rheumatoid arthritis; autoimmune disorders. Synonyms: Fenebrutinib; RG 7845; RG7845; GDC0853; RG-7845; GDC 0853; (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one. Grade: 98%. CAS No. 1434048-34-6. Molecular formula: C37H44N8O4. Mole weight: 664.81. | |
| GDC 0879 | GDC 0879. Group: Biochemicals. Grades: Purified. CAS No. 905281-76-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GDC-0879 | GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases. Group: Inhibitors. Alternative Names: AR-00341677. CAS No. 905281-76-7. Pack Sizes: 2mg. Product ID: S1104. Formula: C19H18N4O2. Smiles: C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| GDC-0879 | GDC-0879. Group: Biochemicals. Alternative Names: 2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-Inden-1-one Oxime. Grades: Highly Purified. CAS No. 905281-76-7. Pack Sizes: 2.5mg. Molecular Formula: C19H18N2O4, Molecular Weight: 334.37. US Biological Life Sciences. | Worldwide |
| GDC-0879 | GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed for some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted for RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic. Synonyms: GDC0879; GDC-0879; GDC 0879. CAS No. 905281-76-7. Molecular formula | |
| GDC-0879 | GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 905281-76-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50864. | |
| GDC-0917 | CUDC-427, also known as, GDC-0917, is an orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic CUDC-427 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains. Synonyms: GDC-0917; GDC0917; GDC 0917; CUDC-427; CUDC427; CUDC-427. Grade: 0.98. CAS No. 1446182-94-0. Molecular formula: C29H36N6O4S. Mole weight: 564.705. | |
| GDC-0927 | GDC-0927 (SRN-927) is a selective oral estrogen receptor degrader (SERD) in a phase I clinical trial for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Study shows well tolerability and clinical effect. Uses: The potential therapy of breast cancer caused by estrogen disorder. Synonyms: SRN-927; SRN 927; SRN927; GDC-0927; GDC 0927; GDC0927. CAS No. 1642297-01-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
| GDC-0927 Racemate | GDC-0927 Racemate is an estrogen receptor degrader, which can effectively inhibit ER-α activity with an IC50 of 0.2 nM. It is used to study ER-related diseases. Synonyms: SRN-927 Racemate; 2H-1-Benzopyran-6-ol, 2-[4-[2-[3-(fluoromethyl)-1-azetidinyl]ethoxy]phenyl]-3-(3-hydroxyphenyl)-4-methyl-. Grade: ≥95%. CAS No. 1443983-36-5. Molecular formula: C28H28FNO4. Mole weight: 461.52. | |
| GDC0941 | GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM. Synonyms: 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; GDC-0941; GDC 0941; GDC0941; RG7321; RG-7321; RG 7321; GNE0941; GNE-0941; GNE 0941; Pictrelisib; Pictilisib. CAS No. 957054-30-7. Molecular formula: C23H27N7O3S2. Mole weight: 513.635. | |
| GDC-0941 Bimesylate | Potent inhibitor of Phosphatidylinositol 3-kinase (PI3K). Group: Biochemicals. Alternative Names: 2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine Methanesulfonate. Grades: Highly Purified. CAS No. 957054-33-0. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GDC-0941 dimethanesulfonate | GDC-0941 dimethanesulfonate is a potent inhibitor of PI3Kα/δ with modest selectivity against p110β and p110γ. It is a novel selective class I phosphatidylinositol-3-kinase (PI3K) inhibitor. It is designed to bind the ATP-binding pocket of PI3K and to prevent formation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), a second messenger that transmits PI3K downstream signals. It causes growth inhibition in a variety of cancer cell lines, including A2780, MDA-MB-361, PC3, and U87MG. It also inhibits the growth of trastuzumab-sensitive and -resistant HER2-amplied cancer cells which harbor p110( mutations or PTEN loss. It also reduces tumor volume in different xenograft models. Synonyms: GDC-0941 dimethanesulfonate; GDC 0941 dimethanesulfonate; GDC0941 dimethanesulfonate; Pictilisib dimethanesulfonate; GDC-0941 (2 MeSO3H salt). Grade: >98%. CAS No. 957054-33-0. Molecular formula: C25H35N7O9S4. Mole weight: 705.85. | |
| GDC-0941, Free Base, PI3K Inhibitor | GDC-0941 is a potent inhibitor of p110a and p110d (IC?? = 3nM). It selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.GDC-0941 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. Folkes, A.J., et al. "The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer." J. Med. Chem. 51: 5522-5532 (2008).GDC-0941 inhibited the growth of >70% ...I., et al. "Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941." Mol. Cancer Ther. 8: 1725-1738 (2009). Group: Biochemicals. Alternative Names: 2- (1H-indazol-4-yl) -6- ( (4- (methylsulfonyl) piperazin-1-yl) methyl) -4-morpholinothieno[3, 2-d]pyrimidine; 4-[2- (1H-Indazol-4-yl) -6-[[4- (methylsulfonyl) piperazin-1-yl]methyl]thieno[3, 2-d]pyrimidin-4-yl]morpholine; GDC 0941; GDC 941; GNE 0941; Pictilisib; Pictrelisib. Grades: Highly Purified. CAS No. 957054-30-7. Pack Sizes: 25mg, 50mg, 100mg. Molecular Formula: C??H??N?O?S?, Molecular Weight: 513.64. US Biological Life Sciences. | Worldwide |
| GDC-0980 | GDC-0980. Group: Biochemicals. Alternative Names: (S)-1-[4-[[2-(2-Aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one; Apitolisib; G 038390; G 038390.1; GDC 0980; GDC 0980.1; GNE 390; RG 7422. Grades: Highly Purified. CAS No. 1032754-93-0. Pack Sizes: 500ug. Molecular Formula: C23H30N8O3S, Molecular Weight: 498.6. US Biological Life Sciences. | Worldwide |
| GDC-0994 | GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. Uses: Antineoplastic agents. Synonyms: GDC0994; GDC 0994; RG7842; RG-7842; RG 7842; Ravoxertinib. CAS No. 1453848-26-4. Molecular formula: C21H18ClFN6O2. Mole weight: 440.863. | |
| GDC-1971 | GDC-1971 is a potent allosteric SHP2 inhibitor for the treatment of RTK/RAS-driven tumors. Synonyms: Spiro[benzofuran-2(3H),4'-piperidin]-3-amine, 1'-[3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-, (3R)-; GDC1971; SHP-1971; (R)-1'-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4'-piperidin]-3-amine; NSC-841576; (3R)-1'-[3-(3,4-Dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-3H-spiro[1-benzofuran-2,4'-piperidin]-3-amine; Migoprotafib. Grade: ≥95%. CAS No. 2377352-49-1. Molecular formula: C25H26N8O. Mole weight: 454.54. | |
| GDC-2394 | GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 could be used to study gouty arthritis. Uses: Scientific research. Category: Signaling pathways. CAS No. 2238822-07-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-148258. | |
| GDC-2992 | GDC-2992 (Compound 28A) is an orally bioavailable androgen receptor (AR) PROTAC degrader. GDC-2992 degrads AR with a DC50 value of 2.7 nM and inhibits proliferation with an IC50 valude of 9.7 nM in VCaPcells. GDC-2992 can be used for prostatic cancer study. (Structure Note: Pink: target protein ligand (HY-130845); Blue: E3 ligase ligand (HY-W1003189A); Black: linker (HY-169975); E3 ligase ligand +linker (HY-169976A))[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: RO7656594. CAS No. 2753651-10-2. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-156751A. | |
| GDC-4379 | GDC-4379, an inhibitor of JAK1, can be used for the study of asthma. Synonyms: N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. CAS No. 2252277-73-7. Molecular formula: C21H18ClF2N7O3. Mole weight: 489.86. | |
| GDC-6036 | GDC-6036 is a selective inhibitor of KRAS G12C that blocks downstream signaling, and exhibits antineoplastic activity. Synonyms: Divarasib; E6S21PVT91; GDC6036; RG6330; 1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one; 1-((3S)-4-((7m)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one; 1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)-4-quinazolinyl)-3-methyl-1-piperazinyl)-. CAS No. 2417987-45-0. Molecular formula: C29H32ClF4N7O2. Mole weight: 622.06. | |
| GDN | GDN, known as Growth Differentiation Factor, serves as a pivotal factor in cellular proliferation and differentiation processes. Its therapeutic applications extend to a wide array of medical conditions, such as oncological disorders and cardiovascular anomalies. GDN's innate ability to stimulate tissue healing and rejuvenation solidifies its significance in the realm of biomedical sciences. Synonyms: Glyco-diosgenin; 2-[2-[(3β,25R)-Spirost-5-en-3-yloxy]ethyl]-1,3-propanediyl bis[4-O-α-D-glucopyranosyl-β-D-glucopyranoside]; glyco-diosgenin (GDN); (2R,2'R,3S,3'S,4S,4'S,5R,5'R,6R,6'R)-6,6'-(((2R,2'R,3S,3'S,4R,4'R,5R,5'R,6R,6'R)-((2-(2-(((4S,5'R,6aR,6bS,8aS,8bR,9S,10R,11aS,12aS,12bS)-5',6a,8a,9-tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl)oxy)ethyl)propane-1,3-diyl)bis(oxy))bis(4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-6,3-diyl))bis(oxy))bis(2-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol). Grade: >99%. CAS No. 1402423-29-3. Molecular formula: C56H92O25. Mole weight: 1165.31. | |
| GDNF family receptor alpha-1 isoform b preproprotein (117-130) | GDNF family receptor alpha-1 isoform b preproprotein (117-130) is a 14-aa peptide. The preproprotein is proteolytically processed to generate the mature receptor. | |
| GDP-2F-Fuc ammonium salt | A competitive inhibitor of fucosyltransferases FUT3, FUT5, FUT6 and FUT7 with Ki values in low micromolar range. This fluorinated GDP-fucose analog inhibits oligosaccharide core fucosylation of N-linked glycans in animal and plant cells. Synonyms: GDP-2-deoxy-2-fluoro-L-fucose ammonium salt. Molecular formula: C16H30FN7O14P2. Mole weight: 625.39. | |
| GDP366 | GDP366 is a novel small molecule compound which potently and selectively inhibited the expression of both survivin and Op18. GDP366 induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Synonyms: 1-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea; GDP 366; GDP-366; GDP366. CAS No. 501698-03-9. Molecular formula: C20H17N5OS. Mole weight: 375.45. | |
| GDP366 | GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 501698-03-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-U00177. | |
| GDP-4-dehydro-6-deoxy-α-D-mannose 3-dehydratase | This enzyme, involved in β-L-colitose biosynthesis, is a unique vitamin-B6-dependent enzyme. In the first step of catalysis, the bound pyridoxal phosphate (PLP) cafactor is transaminated to the pyridoxamine 5'-phosphate (PMP) form of vitamin B6, using L-glutamate as the amino group donor. The PMP cofactor then forms a Schiff base with the sugar substrate and the resulting adduct undergoes a 1,4-dehydration to eliminate the 3-OH group. Hydrolysis of the product from the enzyme restores the PLP cofactor and results in the release of an unstable enamine intermediate. This intermediate tautomerizes to form an imine form, which hydrolyses spontaneously, releasing ammonia and forming the final product. Group: Enzymes. Synonyms: colD (gene name). Enzyme Commission Number: EC 4.2.1.168. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-5009; GDP-4-dehydro-6-deoxy-α-D-mannose 3-dehydratase; EC 4.2.1.168; colD (gene name). Cat No: EXWM-5009. |  |
| GDP-4-dehydro-6-deoxy-D-mannose reductase | This enzyme differs from EC 1.1.1.187, GDP-4-dehydro-D-rhamnose reductase, in that the only product formed is GDP-α-D-rhamnose. D-Rhamnose is a constituent of lipopolysaccharides of Gram-negative plant and human pathogenic bacteria. Group: Enzymes. Synonyms: GDP-4-keto-6-deoxy-D-mannose reductase [ambiguous]; GDP-6-deoxy-D-lyxo-4-hexulose reductase; Rmd; GDP-6-deoxy-D-mannose:NAD(P)+ 4-oxidoreductase (D-rhamnose-forming); GDP-6-deoxy-α-D-mannose:NAD(P)+ 4-oxidoreductase (D-rhamnose-forming). Enzyme Commission Number: EC 1.1.1.281. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0189; GDP-4-dehydro-6-deoxy-D-mannose reductase; EC 1.1.1.281; GDP-4-keto-6-deoxy-D-mannose reductase [ambiguous]; GDP-6-deoxy-D-lyxo-4-hexulose reductase; Rmd; GDP-6-deoxy-D-mannose:NAD(P)+ 4-oxidoreductase (D-rhamnose-forming); GDP-6-deoxy-α-D-mannose:NAD(P)+ 4-oxidoreductase (D-rhamnose-forming). Cat No: EXWM-0189. | |
| GDP-4-dehydro-D-rhamnose reductase | The enzyme, which operates in the opposite direction to that shown, forms a mixture of GDP-α-D-rhamnose and its C-4 epimer, GDP-6-deoxy-α-D-talose. cf. EC 1.1.1.281, GDP-4-dehydro-6-deoxy-D-mannose reductase and EC 1.1.1.135, GDP-6-deoxy-D-talose 4-dehydrogenase. Group: Enzymes. Synonyms: GDP-4-keto-6-deoxy-D-mannose reductase; GDP-4-keto-D-rhamnose reductase; guanosine diphosphate-4-keto-D-rhamnose reductase; GDP-6-deoxy-D-mannose:NAD(P)+ 4-oxidoreductase; GDP-6-deoxy-α-D-mannose:NAD(P)+ 4-oxidoreductase. Enzyme Commission Number: EC 1.1.1.187. CAS No. 9075-56-3. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0089; GDP-4-dehydro-D-rhamnose reductase; EC 1.1.1.187; 9075-56-3; GDP-4-keto-6-deoxy-D-mannose reductase; GDP-4-keto-D-rhamnose reductase; guanosine diphosphate-4-keto-D-rhamnose reductase; GDP-6-deoxy-D-mannose:NAD(P)+ 4-oxidoreductase; GDP-6-deoxy-α-D-mannose:NAD(P)+ 4-oxidoreductase. Cat No: EXWM-0089. | |
| GDP-6-deoxy-a-D-talose | GDP-6-deoxy-a-D-talose. Molecular formula: C16H23N5Na2O15P2. Mole weight: 633.31. | |
| GDP-6-deoxy-D-talose 4-dehydrogenase | This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is GDP-6-deoxy-D-talose:NAD(P)+ 4-oxidoreductase. This enzyme is also called guanosine diphospho-6-deoxy-D-talose dehydrogenase. This enzyme participates in fructose and mannose metabolism. Group: Enzymes. Synonyms: guanosine diphospho-6-deoxy-D-talose dehydrogenase; GDP-6-deoxy-D-talose:NAD(P)+ 4-oxidoreductase. Enzyme Commission Number: EC 1.1.1.135. CAS No. 37250-66-1. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0039; GDP-6-deoxy-D-talose 4-dehydrogenase; EC 1.1.1.135; 37250-66-1; guanosine diphospho-6-deoxy-D-talose dehydrogenase; GDP-6-deoxy-D-talose:NAD(P)+ 4-oxidoreductase. Cat No: EXWM-0039. | |
| GDP-α-D-mannose disodium | GDP-α-D-mannose disodium is the donor substrate for mannosyltransferases and the precursor of GDP-β-L-fucose. GDP-α-D-mannose disodium gives a competitive inhibition with respect to GTP (Ki 14.7 μM) and an uncompetitive inhibition with respect to mannose-1-P (Ki 115 μM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 148296-46-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-N7389B. | |
| GDP-azido-fucose disodium | GDP-Azido-Fucose disodium is a chemically modified donor substrate. GDP-Azido-Fucose disodium can be used to synthesize fluorophore-conjugated GDP-fucose. GDP-Azido-Fucose can be used to study glycosyltransferase reactions[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 944560-34-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-164169A. | |
| GDPβS | GDPβS has been found to exhibit activities as an inhibitor of G-coupled protein. Synonyms: Guanosine-5'-(β-thio)-diphosphate, Sodium salt. Grade: ≥ 90 % by HPLC. Molecular formula: C10H15N5O10P2S (free acid). Mole weight: 459.26 (free acid). | |
| GDP-b-L-glucose ammonium salt | GDP-b-L-glucose ammonium salt is an extensively employed compound, serving as a pivotal tool for examining enzymatic activities and metabolic pathways linked to glucose. This product facilitates profound insights into the intricate mechanisms underlying glucose-related disorders, including diabetes. Synonyms: Guanosine 5'-Diphosphate b-L-glucose ammonium salt; Guanosine 5'-(Trihydrogen Diphosphate) b-L-glucose ammonium salt. Molecular formula: C16H31N7O16P2. Mole weight: 639.40. | |
| GDP-D-galactose | GDP-D-galactose, an indispensable biochemical molecule within the biomedical industry, encompasses a pivotal role in enzymatic reactions. As a substrate for glycosylation-involved enzymes, this vital compound becomes essential for the synthesis of diverse glycoproteins and glycolipids. CAS No. 41432-88-6. Molecular formula: C16H25N5O15P2. Mole weight: 605.34. | |
| GDP-D-glucose disodium salt | GDP-D-glucose sodium salt, a biochemical component for metabolic pathway study and intracellular signaling, plays an imperative role in glucose metabolism. Its potential therapeutic agent property for various diseases is highlighted in recent diabetes and cancer research. And its acknowledged proficiency in regulating the cell differentiation and proliferation further consolidates its prominence. Synonyms: Guanosine-5-diphosphoglucose disodium salt; GDP-Glc disodium salt; Guanosine 5'-(trihydrogen diphosphate), P'-β-D-glucopyranosyl ester, disodium salt. CAS No. 103301-72-0. Molecular formula: C16H23N5O16P2.2Na. Mole weight: 649.31. | |
| GDP-D-glucose phosphorylase | The enzyme may be involved in prevention of misincorporation of glucose in place of mannose residues into glycoconjugates i.e. to remove accidentally produced GDP-α-D-glucose. Activities with GDP-L-galactose, GDP-D-mannose and UDP-D-glucose are all less than 3% that with GDP-D-glucose. Group: Enzymes. Enzyme Commission Number: EC 2.7.7.78. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3290; GDP-D-glucose phosphorylase; EC 2.7.7.78. Cat No: EXWM-3290. | |
| GDP-D-mannose diammonium salt | GDP-D-mannose diammonium salt is a pivotal compound within the biomedical field assuming the fundamental position as a forerunner for the synthesis of GDP-mannose. This molecule is crucially engaged in glycosylation mechanisms. Molecular formula: C16H23N5O16P2.N2H8. Mole weight: 639.4. | |
| GDP-D-mannose disodium | GDP-D-mannose disodium consists of GDP-α-D-mannose (HY-N7389B) and GDP-β-D-mannose. GDP-α-D-mannose serves as a donor substrate for mannosyltransferases and acts as a precursor of GDP-β-L-fucose. GDP-α-D-mannose exerts competitive inhibition on GTP (with a Ki value of 14.7 μM) and non-competitive inhibition on mannose-1-P (with a Ki value of 115 μM). GDP-D-mannose disodium is metabolized to GDP-L-fucose (HY-134433) via GMDS (Gmd) and TSTA3 (WcaG)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 103301-73-1. Pack Sizes: 10 mM * 1 mL in Water; 5 mg; 10 mg. Product ID: HY-N7389A. | |
| GDP-D-mannose disodium salt | GDP-D-mannose disodium salt is an invaluable compound, playing a pivotal role in the research of disorders pertaining to compromised glucose metabolism. Functioning as a critical intermediate within biosynthetic pathways, it specifically facilitates the synthesis of sugar nucleotides. Synonyms: Guanosine 5-diphospho-D-mannose disodium salt; GDP-Man; Guanosine 5'-(trihydrogen diphosphate), P'-D-mannopyranosyl ester, disodium salt. CAS No. 103301-73-1. Molecular formula: C16H23N5O16P2Na2. Mole weight: 649.30. | |
| GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase | The enzyme is involved in the biosynthesis of the O-polysaccharide repeating unit of the bacterium Escherichia coli serotype O86. | |
| GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase | The enzyme is involved in the biosynthesis of the O-polysaccharide repeating unit of the bacterium Escherichia coli serotype O86. Group: Enzymes. Synonyms: WbnK. Enzyme Commission Number: EC 2.4.1.308. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2543; GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase; EC 2.4.1.308; WbnK. Cat No: EXWM-2543. | |
| GDP-Gel / GDP-Agarose | GDP-Gel is the GDP coupled to a polymeric gel by the terminal phosphate, which can be used in the affinity purification of fucosyltransferases. Synonyms: Guanosine- 5'- O- diphosphate, immobilized on a polymeric matrix. | |
| GDP-glucosidase | This enzyme belongs to the family of hydrolases, specifically those glycosidases that hydrolyse O- and S-glycosyl compounds. Group: Enzymes. Synonyms: guanosine diphosphoglucosidase; guanosine diphosphate D-glucose glucohydrolase. Enzyme Commission Number: EC 3.2.1.42. CAS No. 37288-36-1. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3905; GDP-glucosidase; EC 3.2.1.42; 37288-36-1; guanosine diphosphoglucosidase; guanosine diphosphate D-glucose glucohydrolase. Cat No: EXWM-3905. | |
| GDP-L-colitose synthase | The enzyme is involved in biosynthesis of L-colitose, a 3,6-dideoxyhexose found in the O-antigen of Gram-negative lipopolysaccharides, where it catalyses the reaction in the reverse direction. The enzyme also performs the NAD(P)H-dependent epimerisation at C-5 of the sugar. The enzyme from Yersinia pseudotuberculosis is Si-specific with respect to NAD(P)H. Group: Enzymes. Synonyms: ColC. Enzyme Commission Number: EC 1.1.1.356. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0272; GDP-L-colitose synthase; EC 1.1.1.356; ColC. Cat No: EXWM-0272. | |
| GDP-L-fucose | GDP-L-fucose is a pivotal biomolecule acting as a precursory compound to facilitate the synthesis of fucose-containing glycoconjugates implicated in diverse cellular phenomena. Its exceptional significance lies in the research of glycosylation patterns, evaluation of protein functioning repercussions and investigation into possible therapeutic approaches targeting conditions like cancer and inflammation. Synonyms: GDP-b-L-fucose; Guanosine 5-diphospho-b-L-fucose; GDP-Fucose; Guanosine diphosphofucose; Guanosine 5'-diphospho-beta-L-fucopyranose; guanosine 5'-[3-(6-deoxy-beta-L-galactopyranosyl) dihydrogen diphosphate]. Grade: 95%. CAS No. 15839-70-0. Molecular formula: C16H25N5O15P2. Mole weight: 589.34. | |
| GDP-L-fucose | GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway. GDP-L-fucose is associated with diabetes in rats[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 15839-70-0. Pack Sizes: 10 mM * 1 mL in Water; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-134433. | |
| GDP-L-fucose diammonium salt | GDP-L-fucose diammonium salt is an indispensable compound, serving as a vital substrate for fucosyltransferase. This compound intricately contributes to the biosynthesis of fucosylated glycans. Molecular formula: C15H23N5O15P2.N2H8. Mole weight: 623.41. | |
| GDP-L-fucose disodium | GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 148296-47-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-134433A. | |
| GDP-L-fucose disodium salt | Substrate for fucosyltransferase. Synonyms: Guanosine 5'-pyrophosphate, β-L-fucopyranosyl ester Disodium Salt; Guanosine pyrophosphate, L-fucosyl ester Disodium Salt; Guanosine diphosphofucose Disodium Salt; Guanosine diphosphate fucose Disodium Salt; Guanosine 5'-pyrophosphate, L-fucosyl ester Disodium Salt; Guanosine 5'-diphospho-β-L-fucose Disodium Salt; GDP-Fucose Disodium Salt. Grade: ≥95%. CAS No. 148296-47-3. Molecular formula: C16H23N5O15P2Na2. Mole weight: 633.31. | |
| GDP-L-fucose synthase | Both human and Escherichia coli enzymes can use NADH in place of NADPH to a slight extent. Group: Enzymes. Synonyms: GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase; GDP-L-fucose:NADP+ 4-oxidoreductase (3,5-epimerizing). Enzyme Commission Number: EC 1.1.1.271. CAS No. 113756-18-6. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-0178; GDP-L-fucose synthase; EC 1.1.1.271; 113756-18-6; GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase; GDP-L-fucose:NADP+ 4-oxidoreductase (3,5-epimerizing). Cat No: EXWM-0178. | |
| GDP-L-galactose phosphorylase | The enzyme catalyses a reaction of the Smirnoff-Wheeler pathway, the major route to ascorbate biosynthesis in plants. Group: Enzymes. Synonyms: VTC2; VTC5. Enzyme Commission Number: EC 2.7.7.69. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3280; GDP-L-galactose phosphorylase; EC 2.7.7.69; VTC2; VTC5. Cat No: EXWM-3280. | |
Our database is helping our users find suppliers everyday.
